


Manufacturer's Decision Pathway for Reporting Cybersecurity-Related Corrections or Removals from the Field



# MD-VIPER

## Medical Device Vulnerability Sharing

### Stakeholders

including manufacturers, healthcare delivery organizations (HDOs), independent security researchers, regulatory agencies, etc.

### Benefits – Sharing of

- reports on known vulnerabilities
- vetting and evaluation of vulnerabilities
- details of actions taken by others to mitigate vulnerabilities
- medical device cybersecurity education, best practices, mitigation strategies

# MD-VIPER

## MD-VIPER Vulnerability Report for Manufacturers

The *MD-VIPER Vulnerability Report* is designed to serve as an alternate reporting process to FDA's requirements for *21 CFR Part 806* reporting if cybersecurity vulnerabilities are involved.


Manufacturers are not held to *21 CFR Part 806* reporting requirements if

- the manufacturer is a active participant in an ISAO (such as NH-ISAC)
- the manufacturer is conducting a correction/removal to address a cybersecurity vulnerability
- the cybersecurity vulnerability in question has not led to any known serious injuries or deaths
- the manufacturer will meet the timeline criteria for communicating to its customers and then validating and distributing the deployable fix such that the residual risk is brought to an acceptable level

# Medical Device Vulnerability Reporting Workflow


PROVISIONAL: MD-VIPER Vulnerability Report Flow

## by Manufacturer




# Medical Device Vulnerability Reporting Workflow by Non-manufacturer

(researcher, healthcare delivery org, ICS-CERT, patient, etc.)




# Medical Device Vulnerability Reporting Workflow


## Database Update / Analysis / Sharing



# MD-VIPER Site Access



# MD-VIPER Site Access – Member Create / Modify Reports





# MD-VIPER

## MD-VIPER Vulnerability Report for Manufacturers

The *MD-VIPER Vulnerability Report* is designed to serve as an alternate reporting process to FDA's requirements for 21 CFR Part 806 reporting if cybersecurity vulnerabilities are involved.

- ❑ **Questions 1-6 and 8-13** on the MD-VIPER report closely map to the questions in Part 806 reports
- ❑ **Question 7** on the FDA's 806 report asks for a description of events leading the report and any actions taken while question 7 on the MD-VIPER report asks for details about the cybersecurity aspects of the vulnerability
- ❑ **Question 14** has been added to the MD-VIPER report to request that those responses to report questions containing information that could be exploited be treated as *Protected Critical Infrastructure Information* and therefore kept confidential

# MD-VIPER Vulnerability Report for Manufacturers

1. Report Number ..... [REDACTED] 806  
(includes 7 Digit Manufacturer Registration No.)
2. Manufacturer (or Importer)
  - Company Name ..... [REDACTED] 806
  - Street Address ..... [REDACTED] 806
  - City, State Zip ..... [REDACTED], [REDACTED] [REDACTED] 806
  - Contact Name (*Last, First*) ..... [REDACTED] 806
  - Phone ..... [REDACTED] 806
  - e-mail ..... [REDACTED] 806
3. FDA Classification name of the device ..... [REDACTED] 806
4. Marketing status of the device ..... [REDACTED] 806  
(i.e., 510(k), PMA #, preamendment status & device listing number)
5. Unique Device Identifier (UDI) ..... [REDACTED] 806  
(or model/catalog number, lot/serial number)
6. Manufacturer (if different from #2)
  - Company Name ..... [REDACTED] 806
  - Street Address ..... [REDACTED] 806
  - City, State Zip ..... [REDACTED], [REDACTED] [REDACTED] 806
  - Phone ..... [REDACTED], [REDACTED] [REDACTED] 806